What question did this study set out to answer?

To examine the molecular mechanisms through which doxorubicin induces cumulative mitochondrial deterioration and establishes a lasting mitochondrial memory of cardiotoxicity.

March 26, 2020Circulation ResearchOpen Access

Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy

View Full Paper

Ask AI

Bookmark

Why the study?

Anthracyclines such as doxorubicin cause cumulative and progressive cardiomyopathy, prompting an examination of the mitochondrial molecular determinants underlying this toxicity and potential interventions.

Design

Review

Authors

KWKendall B. WallaceUniversity of North Texas VSVilma A. SardãoCenter for Innovation POPaulo J. OliveiraWake Forest University

Discussion

Member takes

Implication

Mitochondrial pathways may guide cardioprotection during doxorubicin therapy; leaves open optimal targets for clinical intervention.

Key Points

To examine the molecular mechanisms through which doxorubicin induces cumulative mitochondrial deterioration and establishes a lasting mitochondrial memory of cardiotoxicity.
Synthesized evidence on anthracycline-induced cardiotoxicity focusing on mitochondrial cellular and molecular pathways.
Evaluated the impact of drug exposure on mitochondrial energetics, redox signaling, quality control pathways, and cell death cascades.
Doxorubicin impairs mitochondrial oxidative phosphorylation and stimulates permeability transition, triggering cellular energetic failure.
Accumulated mitochondrial oxidative stress disrupts autophagy and mitophagy fluxes, culminating in accelerated apoptotic death of cardiac cells.
Targeted pharmacological and nonpharmacological interventions show potential to preserve mitochondrial integrity and mitigate chronic anthracycline cardiotoxicity.

Structured PICO

Population

Cancer patients receiving doxorubicin or anthracycline-based chemotherapy

Intervention

Doxorubicin/anthracycline-based chemotherapy

Outcome

Doxorubicin-induced cardiomyopathy and mitochondrial toxicity

Mitochondrial dysfunction is a central mechanism in doxorubicin-induced cardiomyopathy, and understanding these pathways is essential for developing interventions to mitigate cardiotoxicity.

Cite This Study

Wallace et al. (2020) studied this question.

synapsesocial.com/papers/69ff774bef8139f8ff775f0f https://doi.org/10.1161/circresaha.119.314681

Topics

Cardiomyopathy

View Full Paper

Ask AI

Bookmark

Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider